Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

No longer available 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 22Lung Neoplasms 9Lymphoma, Large-Cell, Anaplastic 4Carcinoma 4Carcinoma, Squamous Cell 2Carcinoma, Large Cell 2Brain Neoplasms 2Adenocarcinoma 2ALK-positive Advanced NSCLC 2Sexual Dysfunction, Physiological 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Meningioma 1Granuloma, Plasma Cell 1Gastrointestinal Neoplasms 1Eunuchism 1Erectile Dysfunction 1Ependymoma 1Disease Progression 1Carcinoma, Pancreatic Ductal 1Breast Neoplasms 1ALK-positive NSCLC 1ALK+ Advanced NSCLC 1

Interventions

Cisplatin 76Radiotherapy 44Cetuximab 40pembrolizumab 39Paclitaxel 34Carboplatin 33Docetaxel 30Fluorouracil 25Radiotherapy, Intensity-Modulated 23Nivolumab 18Drug Therapy 14Radiation 12Erlotinib Hydrochloride 9cemiplimab 8Magnetic Resonance Spectroscopy 8Blood Specimen Collection 8130-nm albumin-bound paclitaxel 8durvalumab 7atezolizumab 7Cyclophosphamide 7Afatinib 7Surveys and Questionnaires 6Surgical Procedures, Operative 6Panitumumab 6Leucovorin 6Esophagectomy 6Chemoradiotherapy 6fludarabine 5aldesleukin 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × brigatinib × Clear all
NCT02737501 2021-08-20

ALTA-1L

Takeda

Phase 3 Completed
275 enrolled 23 charts 1 FDA
Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT02784158 2018-02-06

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Takeda

No longer available
Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡